ExonHit, BioMerieux Kill Colon Cancer Program, Continue to Develop Prostate Cancer Dxs

The companies said that "final results from the colon cancer program did not reach the level of performance we were aiming to achieve." The firms, both based in France, are co-developing microarray-based tests that screen for a variety of cancer biomarkers in blood.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.